A complete blood count (CBC) cannot detect ovarian cancer. This routine blood test measures red blood cells, white blood cells, and platelets, but it does not look for cancer cells or tumor markers. You can have ovarian cancer, even at an advanced stage, and still receive a completely normal CBC result.
That said, a CBC can sometimes show indirect abnormalities that prompt further investigation. Understanding what those abnormalities are, and what tests actually do detect ovarian cancer, can help you make sense of your lab results.
What a CBC Actually Measures
A CBC counts the major types of cells circulating in your blood: red blood cells (and their hemoglobin, which carries oxygen), white blood cells (which fight infection), and platelets (which help with clotting). It tells your doctor whether these counts fall within normal ranges. It says nothing about whether abnormal cells are growing in your ovaries, your abdomen, or anywhere else. There is no component of a standard CBC that identifies a tumor.
Indirect Signs That Sometimes Appear
While a CBC won’t diagnose ovarian cancer, certain shifts in blood cell counts show up more often in women who have it. These changes are not specific to ovarian cancer and can be caused by dozens of other conditions, but they’re worth understanding.
High Platelet Count
About 31% of ovarian cancer patients have an elevated platelet count (above 450,000 per cubic millimeter) at diagnosis. This happens because tumors can produce inflammatory signals that stimulate the liver to ramp up platelet production. Research published in the journal Blood found that women with ovarian cancer and high platelet counts had significantly shorter survival (2.62 years versus 4.65 years) compared to those with normal counts, suggesting the elevated platelets aren’t just a bystander effect. Platelets may actually help tumors grow and spread. Still, a high platelet count on its own is far more likely to result from infection, iron deficiency, or inflammation than from cancer.
Low Hemoglobin (Anemia)
Anemia is common in gynecological cancers. In a study of 320 women with gynecological cancers (ovarian, cervical, and endometrial), about 59% were anemic before any treatment began, with hemoglobin levels below 12 g/dL. Among the 106 ovarian cancer patients in that group, roughly 57% had anemia. Cancer-related anemia can develop because tumors divert the body’s resources, cause chronic inflammation, or in some cases lead to internal bleeding. But anemia is one of the most common lab findings in medicine, period. It could just as easily point to heavy periods, low iron intake, or a chronic condition.
Shifted White Blood Cell Ratios
The ratio between two types of white blood cells, neutrophils and lymphocytes, tends to shift in people with cancer. Ovarian tumors trigger inflammation that increases neutrophils while suppressing lymphocytes, the immune cells that normally help fight cancer. A high neutrophil-to-lymphocyte ratio has been linked to worse outcomes in ovarian cancer patients. Your CBC does report these individual counts, but doctors don’t routinely calculate this ratio during standard screening. It’s used more as a prognostic tool once cancer is already suspected or diagnosed.
Why a Normal CBC Doesn’t Rule It Out
The majority of women with early-stage ovarian cancer will have a CBC that looks perfectly normal. Even many women with advanced disease won’t show obvious abnormalities on this test. Ovarian cancer grows in the pelvis and abdominal cavity. It doesn’t typically flood the bloodstream with signals that a basic cell count would catch. Relying on a normal CBC for reassurance about ovarian cancer would be a mistake.
Blood Tests That Are More Relevant
The blood test most commonly associated with ovarian cancer is CA-125, a protein shed by many ovarian tumors. About 80% of ovarian cancers produce elevated CA-125 levels, using a standard cutoff of 35 U/mL. The test picks up 92% of advanced-stage cancers but only about 50% of early-stage ones. That gap is a real limitation.
CA-125 also isn’t very precise in the other direction. Endometriosis, fibroids, liver disease, and even menstruation can push CA-125 above the threshold. In asymptomatic women screened with CA-125 alone, only about 1 in 100 positive results actually turns out to be cancer. For this reason, major medical organizations including the American College of Obstetricians and Gynecologists and the U.S. Preventive Services Task Force recommend against routine ovarian cancer screening in average-risk women with any current test, including CA-125. The false positives lead to unnecessary surgeries that carry their own risks.
CA-125 is most useful when a doctor already suspects ovarian cancer based on symptoms or imaging. In that context, it helps guide diagnosis and later serves as a way to monitor whether treatment is working.
How Ovarian Cancer Is Actually Diagnosed
Diagnosis relies on a combination of tools rather than any single test. Transvaginal ultrasound is typically the first imaging step. A meta-analysis of multiple studies found it has a pooled sensitivity of 92% and specificity of 89% for distinguishing cancerous from non-cancerous masses in the ovaries. When a suspicious mass is found, CT scans or MRI help determine whether the cancer has spread.
The definitive diagnosis comes from a biopsy, where tissue is examined under a microscope. In many cases, this happens during the same surgery that removes the tumor. No blood test, whether a CBC, CA-125, or any other panel, can confirm ovarian cancer on its own. Blood tests provide supporting information, but tissue analysis is what gives the actual answer.
What Symptoms to Pay Attention To
Because no reliable screening test exists for average-risk women, awareness of symptoms becomes especially important. Ovarian cancer was once called a “silent killer,” but most women do experience symptoms. They’re just easy to attribute to other things. Persistent bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency are the most recognized warning signs. The key word is persistent: these symptoms occurring nearly every day for two to three weeks, especially if they’re new for you, warrant a conversation with your doctor. At that point, your doctor can order targeted testing like CA-125 and a transvaginal ultrasound rather than relying on routine bloodwork that was never designed to find this disease.